Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | CKS1B | P61024 | 1/20 | 0.51 |
| ▸ | SKP1 | P63208 | 1/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30316309 | 1.00 | MAP4K4 (0.51) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL15252426 | 0.94 | CKS1B (0.54) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL17055304 | 0.93 | MAP4K4 (0.59) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL17054763 | 0.93 | MAP4K4 (0.59) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL4828925 | 0.87 | JAK3 (0.52) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL3708015 | 0.87 | CTSK (0.52) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL952604 | 0.86 | CKS1B (0.51) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL952899 | 0.86 | CKS1B (0.51) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL18291318 | 0.85 | CKS1B (0.41) | MAP4K4CKS1BSKP1SKP2BTK | |
| SCHEMBL18291317 | 0.85 | CKS1B (0.41) | MAP4K4CKS1BSKP1SKP2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-8415355-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415355-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | MAP4K4 191/4885CKS1B 61/4885SKP1 602/4885 |
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | CDK4, CDK2, CDKL1 | MAP4K4 50/4885CKS1B 44/4885SKP1 158/4885 |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | MAP4K4 119/4885CKS1B 38/4885SKP1 468/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAP4K4 88/4885CKS1B 49/4885SKP1 204/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAP4K4 88/4885CKS1B 49/4885SKP1 204/4885 |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAP4K4 88/4885CKS1B 49/4885SKP1 204/4885 |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAP4K4 88/4885CKS1B 49/4885SKP1 204/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAP4K4 88/4885CKS1B 49/4885SKP1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.